Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Overview
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Allergan Plc
AlzeCure Pharma AB
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
F. Hoffmann-La Roche Ltd
Handok Inc
Merck & Co Inc
Neurodegeneration Therapeutics Inc
Oncology Venture A/S
Pfizer Inc
Purdue Pharma LP
Rottapharm Biotech Srl
Sien Biopharmaceuticals Inc
Tizia Life Sciences Plc
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles
ACD-855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Products
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kise Receptor Type 1 or TRK1 Transforming Tyrosine Kise Protein or Tropomyosin Related Kise A or Tyrosine Kise Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Allergan Plc, H1 2020
Pipeline by AlzeCure Pharma AB, H1 2020
Pipeline by AnHeart Therapeutics Inc, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Pipeline by Dompe Farmaceutici SpA, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Handok Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Neurodegeneration Therapeutics Inc, H1 2020
Pipeline by Oncology Venture A/S, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Purdue Pharma LP, H1 2020
Pipeline by Rottapharm Biotech Srl, H1 2020
Pipeline by Sienna Biopharmaceuticals Inc, H1 2020
Pipeline by Tiziana Life Sciences Plc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020